AGP Executive Report
Last update: 5 hours agoMedical Research Funding Push: A Columbus cancer survivor joined patient advocates urging Congress to protect medical research budgets. Neurology Treatment Updates: Real-world registry data suggest C5 inhibitors eculizumab and ravulizumab sharply cut relapses in AQP4-antibody NMOSD, with no meningococcal infections reported. Epilepsy Pipeline: Biohaven shared new clinical signals for opakalim, a selective Kv7.2/7.3 activator, across multiple epilepsy groups ahead of upcoming pivotal studies. Better Diagnosis for Myelitis: New proposed criteria aim to replace the catch-all “transverse myelitis” approach with clearer inflammatory myelitis definitions to reduce misdiagnosis. Access and Affordability: Australia expanded PBS coverage for migraine prevention drug Emgality, slashing costs for eligible patients. Counterfeit-Medicine Crackdown: Pakistan’s cabinet approved a nationwide track-and-trace system with 2D barcodes and serialisation to verify medicines end-to-end. Care Delivery Pressure: In Georgia, Medicaid reimbursement cuts tied to CareSource threaten therapy access for children, with clinics warning they may stop taking patients.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[The Pharma Patent Cliff Explained: What It Is and How Companies Navigate It]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/8d872c38f749831638ab4b10061cf48065037e1d-1280x804.jpg)
